A recent pre-clinical study showed the ability of TRAIL-expressing MSCs to kill classical and primary NB cell lines in vitro and to successfully migrate to tumor sites in vivo, although a reduction of NB tumor growth in xenotransplantation experiments could only be reached in combination with the anti-cancer drug bortezomib [46]. This evidence concerns the gene TNFSF10 and neoplasm.